JP2009517386A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517386A5
JP2009517386A5 JP2008542377A JP2008542377A JP2009517386A5 JP 2009517386 A5 JP2009517386 A5 JP 2009517386A5 JP 2008542377 A JP2008542377 A JP 2008542377A JP 2008542377 A JP2008542377 A JP 2008542377A JP 2009517386 A5 JP2009517386 A5 JP 2009517386A5
Authority
JP
Japan
Prior art keywords
aag
pharmaceutical suspension
phosphatidylcholine
ester
block copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2008542377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517386A (ja
Filing date
Publication date
Priority claimed from US11/595,005 external-priority patent/US7648976B2/en
Application filed filed Critical
Publication of JP2009517386A publication Critical patent/JP2009517386A/ja
Publication of JP2009517386A5 publication Critical patent/JP2009517386A5/ja
Abandoned legal-status Critical Current

Links

JP2008542377A 2005-11-23 2006-11-16 １７−アリルアミノ−１７−デメトキシゲルダナマイシン多形体及び製剤 Abandoned JP2009517386A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73922505P 2005-11-23 2005-11-23
US80952706P 2006-05-30 2006-05-30
US11/595,005 US7648976B2 (en) 2005-11-23 2006-11-08 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
PCT/US2006/044746 WO2007061878A2 (en) 2005-11-23 2006-11-16 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations

Publications (2)

Publication Number Publication Date
JP2009517386A JP2009517386A (ja) 2009-04-30
JP2009517386A5 true JP2009517386A5 (enExample) 2010-01-07

Family

ID=38067791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542377A Abandoned JP2009517386A (ja) 2005-11-23 2006-11-16 １７−アリルアミノ−１７−デメトキシゲルダナマイシン多形体及び製剤

Country Status (8)

Country Link
US (1) US7648976B2 (enExample)
EP (1) EP1951223A4 (enExample)
JP (1) JP2009517386A (enExample)
KR (1) KR20080089357A (enExample)
AU (1) AU2006318771A1 (enExample)
BR (1) BRPI0618873A2 (enExample)
CA (1) CA2629196A1 (enExample)
WO (1) WO2007061878A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
JP2010516282A (ja) * 2007-01-26 2010-05-20 コーサン バイオサイエンシーズ， インコーポレイテッド 工学的生合成によるマクロラクタム
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
CN109715141A (zh) * 2016-07-08 2019-05-03 兰迪斯制药公司 治疗和/或预防溶酶体贮积病和其它单基因代谢性疾病的组合物和方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
ATE334119T1 (de) * 2001-03-30 2006-08-15 Us Health Geldanamycinderivate zur krebsbehandlung
WO2002087619A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CN100378079C (zh) * 2001-09-24 2008-04-02 康福玛医药公司 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US6887993B1 (en) * 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2006034147A2 (en) 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
JP2008531708A (ja) 2005-02-28 2008-08-14 コーザン バイオサイエンシス インコーポレイテッド １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤
EP1871361A2 (en) * 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same

Similar Documents

Publication Publication Date Title
US20100003332A1 (en) Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
JP2011037876A5 (enExample)
JP2009512663A5 (enExample)
NZ592383A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
JP2008280352A (ja) 溶解性または経口吸収性の改善された組成物
ES2307722T3 (es) Metodo para obtener microparticulas que contienen un inhibidor de n+,k+atp-asa.
JP2010047579A5 (enExample)
JP2010510241A5 (enExample)
JP2010241820A (ja) 保護被膜を有する再分散性超微粒状フィルムマトリックス
RU2009128206A (ru) Содержащая ревапразан твердая дисперсия и способ ее получения
JP2016513625A5 (enExample)
JP2013505233A5 (enExample)
JP2011506587A5 (enExample)
US10596263B2 (en) Pazopanib formulation
JP2009517386A5 (enExample)
JP3881640B2 (ja) ロラタジンを含むドライシロップ剤
KR101730865B1 (ko) 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
JP2008013480A (ja) 薬物含有微粒子およびその製造方法
CN106999429B (zh) 纳米悬浮剂制剂
WO2012002547A1 (ja) ボセンタン固体分散体
JP5297194B2 (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
CN102048702B (zh) 一种联苯双酯纳米结晶制剂及其制备方法
JPH107558A (ja) 溶解性改善製剤
JP2008522972A5 (enExample)
KR101021619B1 (ko) 안정성이 증진된 알파-리포익산의 나노입자 제제 및 그제조방법